Home
Contact
Chemotherapy
Home
Chemotherapy
Filter by
Categories
Tags
Authors
Show all
All
Editorials
New Trials
Ongoing Trials
Trial Results
All
Anal cancer
Breast cancer
Caregiving
Chemotherapy
Chronic lymphocytic leukemia
COVID-19
De-escalation
Esophagus cancer
GI cancer
Head and neck cancer
HER2+ breast cancer
Hormone therapy
Immune system therapy
Immunotherapy
In memory
Kidney cancer
Late Effects
Leukemia
Lymphoma
Mammography
Mantle cell lymphoma
Melanoma
MRI
Neuropathy
Pancreatic cancer
Pancreatic cysts
Personalized medicine
Personalized screening
Precision medicine
Prevention
Prostate cancer
Renal cell carcinoma
Screening
Side effects
Squamous cell carcinoma
Surveillance
Survivorship
Targeted therapy
Throat cancer
Triple-negative breast cancer
Tumor test
All
Akshay Hanikhindi
Diane Dragaud
ecogacrinnews2
Katie Heller
wpengine
October 2, 2020
October 2, 2020
Categories
Trial Results
Trial Results: For women with breast cancer in the TAILORx trial, cognitive decline from chemo was early and abrupt but did not get worse over time. Cognition also declined in the group on hormone therapy alone.
Cognitive loss—or ‘brain fog’—involves memory problems, a lack of mental clarity, and difficulty keeping one’s focus. Cancer-related brain fog is common during treatment. This study dispels the idea that it is only from chemotherapy.